Dror Bashan - 03 Sep 2025 Form 4 Insider Report for Protalix BioTherapeutics, Inc. (PLX)

Role: PRESIDENT AND CEO, Director
Signature: /s/ Joseph R. Magnas, Attorney-in-Fact
Issuer symbol: PLX
Transactions as of: 03 Sep 2025
Net transactions value: $0
Form type: 4
Filing time: 04 Sep 2025, 17:00:10 UTC
Previous filing: 20 Oct 2023
Next filing: 23 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Bashan Dror	PRESIDENT AND CEO, Director	C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET SCIENCE PARK, POB 455, CARMIEL, ISRAEL	/s/ Joseph R. Magnas, Attorney-in-Fact	04 Sep 2025	0001781450

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PLX	Common Stock	Award		+195,000	+9.1%		2,344,418	03 Sep 2025	By Trust	F1, F2
holding	PLX	Common Stock						132,516	03 Sep 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PLX	Stock Option (Right to Buy)	Award	$0	+340,000		$0.000000	340,000	03 Sep 2025	Common Stock	340,000	$1.64	Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the "Plan"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant and are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan.
F2	To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.
F3	The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan.
F4	Does not include (i) options to purchase 160,000 shares of common stock at an exercise price equal to $4.69 per share that expire on June 30, 2029 and (ii) options to purchase 750,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032.